Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomania or Mild Mania

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
The purpose of this research study is to evaluate the safety, tolerability, and efficacy of divalproex extended release compared to placebo (sugar pill without medication) in the treatment of bipolar disorder with moderate to severe hypomania or mild mania. Divalproex extended release is approved by the United States Food and Drug Administration (FDA) for the treatment of epilepsy and for prevention of migraine headaches.
Epistemonikos ID: cc27a29c93e29e945c568095d4a821d9fac8fbbe
First added on: May 04, 2024